Every woman is different and nearly half of women could have elevated risk or complicating factors that may require a personalized approach to screening and diagnosis. Are you prepared to meet their personalized needs?

With the GE Breast Health Advantage, you’ll have access to an adaptable portfolio of technologies, insights and services to help you serve the personalized breast health needs of the women in your patient community, including those who may have elevated risks or complicating factors.

Download the Brochure >


It's not easy.

The National Cancer Institute estimates that the number of breast cancers diagnosed in the U.S will increase by about 50 percent by 2030.

The competition for patients and physicians is fierce. The reimbursement landscape is shifting. Technology continues to evolve and improve, but where it best fits in the care pathway is not always clear. The Patient Protection and Accountable Care Act is providing coverage to an estimated incremental 746,000 women for important screenings by 20191 , yet the U.S. Preventative Services Task Force (USPSTF) recommends reductions in the frequency of screening. And, nearly half of all women could have elevated risks or complicating factors2,3  that may require a screening and diagnostic personalized approach.

In addition to managing these market challenges, you may want to focus on lowering recall rates, shortening times from screening to diagnosis, and gaining important insights that will help inform treatment decisions for each woman.

In today’s cost-constrained environment, it’s important to ensure your investments in strengthening and expanding your capabilities pay off for your facility, and work hard for your patients. That’s why it’s critical to have a trusted, committed team to help you deliver the care your patients need — and to help you meet your financial and operational objectives.

That’s why we offer the GE Breast Health Advantage.


1 Banjo, Solomon. The Advisory Board Company. Imaging Performance Partnership. (2014). Breast Imaging Update: Current Market Outlook and Update on Digital Breast Tomosynthesis.

2 Tabár L, et al. (2011). Swedish Two County Trial: Impact of Mammographic. 260: 658 63.

3 American Cancer Society. (2015) Cancer Facts & Figures 2015.

4 National Cancer Institute at the National institutes of Health. (2015, April 23). Study Forecasts New Breast Cancer Cases by 2030.



Screening Phase

Offering advanced technologies, such as Digital Breast Tomosynthesis, Molecular Breast Imaging and Invenia™ ABUS, to supplement traditional mammography screening may help improve cancer detection in patients with elevated risks or complicating factors. Having an adaptable mix of advanced technologies can help enable your efforts to obtain the information needed to confidently assess each patient.

View Full group


Diagnosis & Biopsy Phase

Our offering was designed to help enable your multidisciplinary breast care team confidently detect breast disease and to help you decrease the time to diagnosis. For example, GE’s Breast Health Rapid Assessment program can help you identify opportunities to optimize patient flow and experience.

View Full group


Pathology, Staging & Treatment Planning Phase

The GE Breast Health Advantage can help your multidisciplinary breast care team contribute to their patient’s care with a personalized treatment approach. For example, clinicians can work with GE’s robust Centricity and Omnyx technologies to pursue seamless data sharing and optimized collaboration, from initial presentation to communication of pathology results.

View Full group


Treatment Monitoring & Surveillance Phase

Advanced imaging technologies, such as GE’s molecular breast imaging, PET/CT and PET/MR, can help clinicians to carefully monitor patients’ treatment with precise visualization and tracking of metabolic activity and disease progression. Armed with data, such as reliable quantitative SUV values, clinicians can obtain important insights on treatment effectiveness to help optimize care.

View Full group

Care Personalization

Are you equipped to meet the personalized needs of each woman?

Your patient population is very diverse. Different sizes, shapes, ethnicities and ages. This population has a similarly diverse mix of risk profiles, such as dense breast tissue, calcifications, fatty tissue, BRCA mutations, and family history. As many as 46 percent of women have dense breast tissue1 and many more may have other complicating factors that can impact the effectiveness of standard screening and diagnostic methodologies.1,2

Clearly, recalls and false negatives aren’t good for your patients or for your breast health program, nor are extended waiting times to achieve a confident diagnosis.

It can potentially impact clinical outcomes, frustrate your clinical staff, diminish patient experience, and perhaps, negatively impact your reputation with other women in your community.

Meeting the needs of every woman can be challenging and the GE Breast Health Advantage can help.


1 Pisano, E.D., Gatsonis, C., et. al. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening. N Engl J Med 2005;353.1-11

2 American Cancer Society website. Mammograms and Other Breast Imaging Tests. Revised April 9, 2015.

Clinical Outcomes

Do you have the information needed to enhance clinical
outcomes and inform treatment planning?

Studies show a second opinion or collaborating with the care team has the potential to improve diagnosis and treatment for nearly one in ten patients.Helping your patients achieve positive clinical outcomes starts with gaining a clear image of the breast to identify potential abnormalities. If an abnormality presents, you want to be able to rule-in or rule-out cancer and to gain the insights needed to inform treatment planning and monitoring. It’s important to have the right mix of technologies available to help attain the information you need to confidently screen, diagnose, stage, plan treatments and monitor your patients.

Here are a few ways the GE Breast Health Advantage can help.


Imaging Technologies

We have an adaptable offering of low and no dose, advanced imaging technologies to deliver superb image quality to help visualize small abnormalities, masses and architectural distortions including: the only FDA-approved automated ultrasound technology for dense breasts, Molecular Breast Imaging, Digital Tomosynthesis, Contrast-Enhanced Spectral Mammography, MR, PET/MR, CT and PET/CT.

For example, the LOGIQ family of hand-held ultrasound products offers consoles that are specifically designed with tools to address the needs of clinicians focused on breast health.

Shear wave elastography enables non–invasive assessment of lesion stiffnessin breast while integrating smoothly with department workflow. The Breast Productivity Package helps provide excellent efficiency and standardization to lesion reporting.

SenoClaireTM Digital Breast Tomosynthesis

SenoClaire is a three-dimensional imaging technology that uses a low-dose short X-ray sweep around the compressed breast with only nine exposures. For average and large breasts (above 45 mm), GE SenoClaire’s 3D view dose is at least 40 percent lower than Hologic Selenia Dimensions.3


Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. The Clarient Insight™ Dx Mammostrat™ is a test for estimating the risk for recurrence in hormone-receptor positive, early stage breast cancer that is independent of proliferation and grade.


Comprehensive asset and financial service programs help keep your technology operating at optimal performance levels, provide training and education to your staff, and help avoid technological obsolescence.


1 Newman EA, Guest AB, Helvie MA, et al. (2006) Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 107:2346–2351.
1 Romanoff, et al. (2014, May). Breast Pathology Review: Does It Make a Difference? Annals of Surgical Oncology.

2 National Cancer Institute at the U.S. National Institutes of Health. Breast Cancer Surveillance Consortium. (2014, July 9). Abnormal Interpretations for 2,061,691 Screening Mammography Examinations from 2004 - 2008 -- based on BSBC data through 2009. Retrieved on April 30, 2015 from http://breastscreening.cancer.gov/statistics/benchmarks/screening/2009/table3.html.

3 Comparison data determined on a phantom. N.W. Marshall and H. Bosmans, Medical Physics UZ Leuven. Application of the draft EUREF protocol for Quality Control of digital breast tomosynthesis (DBT) systems. BHPA 2014.

Timeliness & Efficiency

Are you looking for ways to improve the timeliness and efficiency of care delivery?

Delivering results quicker and more efficiently can benefit patients and your organization. It can help reduce patient anxiety due to the wait for results, potentially enable quick action on abnormal results, enhance workflow to increase capacity to handle more patients, and optimize staff and asset utilization.

Here are a few ways the GE Breast Health Advantage can help.



Omnyx, an integrated digital pathology solution, addresses the scale, reliability and process requirements of pathologists, enabling single and multi-site pathology departments to benefit from workflow efficiencies and greater access to peers in the field.

GE announced that Omnyx will be integrated into Clarient’s current laboratory. By combining the advanced molecular analysis of Clarient with Omnyx’s software, the pathology community will have a data-rich pool of imaging, enhancing the collaboration and gaining insights for more individualized cancer therapy.

Centricity™ Universal Viewer Breast Imaging

Centricity Universal Viewer Breast Imaging is a multi-vendor, multimodality application for reading 2D, 3D breast images that helps hospitals, health systems and imaging centers optimize workflow, improve productivity and provide enterprise and community-wide access to breast images. It delivers a single application for screening and diagnosis that integrates breast imaging into the overall reading workflow, helping to reduce swivel chair and eliminate independent workstations and storage.

Breast Health Rapid Assessment

The Breast Health Rapid Assessment, conducted by GE Healthcare Partners, can help identify ways to improve operational workflows to expedite screening-to-diagnosis results.

Invenia™ ABUS

Unlike traditional hand-held ultrasound, ABUS screening exams can be completed in approximately 15 minutes and typically are performed by mammography technologists. Because the exam is automated, results are reproducible and do not rely on the expertise of a sonographer.


1. Hamady ZZ, et al. (2005, February). Surgical Pathological Second Opinion in Thyroid Malignancy: Impact on Patients’ Management and Prognosis. Eur J Surg Oncol. 31(1): 74-7.

2. Hillman, Dr. Bruce, and Dr. Bhavik Pandya. (2013, November). “Radiologists’ Burden of Inefficiency Using Conventional Imaging Workstations.”  Journal of the American College of Radiology.

Case Studies

Thought Leadership


The Invenia™ ABUS is indicated as an adjunct to mammography for breast cancer screening in asymptomatic women for whom screening mammography findings are normal or benign (BI-RADS® Assessment Category 1 or 2), with dense breast parenchyma (BI-RADS Composition/Density 3 or 4), and have not had previous clinical breast intervention. The device is intended to increase breast cancer detection in the described patient population. The Invenia ABUS may also be used for diagnostic ultrasound imaging of the breast in symptomatic women. See the device manual for detailed information, contraindications, warnings, precautions, potential adverse events.

SenoClaire™ acquires 2D images and also acquires multiple projection views to product 3D DBT images suitable for screening and diagnosis of breast cancer. SenoClaire can be used for the same clinical applications as traditional mammographic systems for screening mammograms. Note: A screening examination will consist of a 2D image set consisting of a craniocaudal view and a mediolateral oblique view, or a 2D craniocaudal view and 3D DBT mediolateral oblique image set. The SenoClaire Digital Breast Tomosynthesis (DBT) option for Senographe Essential FFDM system may also be used for additional diagnostic workup of the breast. See the device manual for detailed information, contraindications, warnings, precautions, potential adverse events.